top of page
Projects:
Alpha-4 Integrin Antagonism
AVA7367: Lead Development Compound
• A novel, proprietary, potent, orally available small molecule dual antagonist of the a4b1 and a4b7 integrins
• Pharmacological profile and IND enabling studies support development for Inflammatory Bowel Disease (IBD) and other Inflammatory conditions.
• Licensing/acquisition inquires welcome
bottom of page